The Qualification and Disqualification of Patients and Events in Long-Term Cardiovascular Clinical Trials

M. Gent; D. L. Sackett

doi:10.1055/s-0039-1687187

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1979; 41(01): 123-134
DOI: 10.1055/s-0039-1687187

Dedication

Schattauer GmbH

The Qualification and Disqualification of Patients and Events in Long-Term Cardiovascular Clinical Trials

M. Gent

¹Department of Clinical Epidemiology and Biostatistics, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada

,

D. L. Sackett

¹Department of Clinical Epidemiology and Biostatistics, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada

› Author Affiliations

Abstract

Full Text

References

References
1 Anturane Reinfarction Trial Research Group. 1978; Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. New England Journal of Medicine 298: 289.
2 Canadian Cooperative Study Group. 1978; A randomized trial of aspirin and sulfinpyrazone in threatened stroke. New England Journal of Medicine 299: 53.
3 Cochrane A.L.. 1972 Effectiveness and Efficiency. The Nuffield Provincial Hospitals Trust.
4 European Working Party. 1971; Streptokinase in recent myocardial infarction: A controlled multicentre trial. British Medical Journal 3: 325.
5 Gent M., and Hirsh J.. 1979; Definition of high risk/high response population for stroke in patients with transient ischemic attacks. Thrombosis et Diathesis Haemorragica 40: 43.
6 Genton E., Gent M., Hirsh J., and Harker L.A.. 1975; Platelet-inhibiting drugs in the prevention of clinical thrombotic disease. New England Journal of Medicine, 293, 1174 1236: 1296.
7 Haynes R.B., Sackett D. L., Gibson E.S., Taylor D.W., Hacker B.C., Roberts R.S., and Johnson A.L.. 1976; Improvement of medication compliance in uncontrolled hypertension. Lancet 1: 1265.
8 Johnson A.L., Taylor D.W., Sackett D.L., Dunnet C.W., and Shimizu A.G.. 1978; Self-recording of blood pressure in the management of hypertension. Canadian Medical Association Journal 119: 1034.
9 Kaegi A., Pineo G.F., Shimizu A., Trivedi H., Hirsh J., and Gent M.. 1975; The role of sulfinpyrazone in the prevention of arteriovenous shunt thrombosis. Circulation 52: 497.
10 Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., Mantel N., McPherson K., Peto J., and Smith P.G.. 1976; Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. British Journal of Cancer 34: 585.
11 Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., Mantel N., McPherson K., Peto J., and Smith P.G.. 1977; Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and Examples. British Journal of Cancer 35: 1.
12 Sackett D. L.. 1972. Design, measurement and analysis in clinical trials. In: Hirsh J., Cade J. F., Gallus A. S., and Schonbaum E.. (eds.). Platelets, Drugs and Thrombosis. Karger; Basel.:
13 Schwartz D., and Lellouch J.. 1967; Explanatory and pragmatic attitudes in therapeutic trials. Journal of Chronic Diseases 20: 637.
14 Simon T.L., Ware J.H., and Stengle J. M.. 1973; Clinical trials of thrombolytic agents in myocardial infarction. Annals of Internal Medicine 79: 712.
15 Veterans Administration Cooperative Study Group on Antihypertensive Agents. 1967; Effects of treatment on morbidity in hypertension. I. Results in patients with diastolic blood pressures averaging 90 through 114 mm Hg. Journal of the American Medical Association. 213: 1143.